DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. Improved Return on Investment (ROI) Industry-academic partnerships can enhance the financial return on drug development investments.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

The Pharma Data

DECEMBER 22, 2020

Since 2013, Rakuten Medical, Inc. has been using an exclusively licensed antibody complex to develop new cancer therapies based on its Illuminox TM technology platform. For more information, visit www.rakuten-med.com. About ASP-1929.

Clinical Trials 52

Clinical Trials Therapies Trials Production 52

PPD

JULY 9, 2024

Drug developers need to staff RA teams that can handle regular lifecycle maintenance ebbs and flows across lifecycle maintenance tasks, and plan for a workload that sometimes requires senior-level expertise, while at other times is much more suited to support staff. However, completing this work is only half the challenge.

Compliance 52

Compliance Production Clinical Research Marketing 52

The Pharma Data

JANUARY 7, 2021

About ASP-1929 Since 2013, Rakuten Medical, Inc. has been using an exclusively licensed antibody complex to develop new cancer therapies based on its Illuminox TM technology platform. For more information, visit www.rakuten-med.com.

Clinical Trials 40

Clinical Trials Therapies Trials Licensing 40

The Pharma Data

NOVEMBER 29, 2020

To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. Human Cytomegalovirus Resistance to Antiviral Drugs. Available at: [link] 2 Nephrol Dial Transplant (2013) 28: 2908–2918 3 Centers for Disease Control and Prevention.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

The Pharma Data

DECEMBER 15, 2020

Pancreatic cancer remains an area of unmet medical need, with no new approved therapies since the approval of nab-paclitaxel (Abraxane ® ) in combination with gemcitabine for first-line treatment in 2013 and Onivyde ® in combination with fluorouracil and leucovorin for second-line treatment in 2015. About BioLineRx BioLineRx Ltd.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

DECEMBER 27, 2020

We also market or plan to market in China additional oncology products licensed from Amgen Inc., 2013 Feb 7;121(6):893. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA ® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. 2012 Aug 2;120(5):947-59.

Production 52

Production Therapies Treatment Drugs 52